-
New Clinical Trial Explores Botulinum Toxin for Stroke and Brain Injury-Related Leg Spasticity
A new randomized trial is investigating whether NT 201, a botulinum toxin therapy, can safely and effectively ease lower limb spasticity in people recovering from stroke or traumatic brain injury.
-
New Phase III Trial to Test Innovative Peptide-Free Chemotherapy Delivery for Peritoneal Cancers
A new Phase III trial, IMPACT, is investigating whether delivering mitomycin as a pressurized aerosol directly into the abdominal cavity can improve outcomes for patients with unresectable appendix or colorectal cancer that has spread to the peritoneum.
-
New Clinical Trial Explores Advanced Combination Therapy for Aggressive Lymphoma
A new Phase 3 clinical trial is comparing two promising drug combinations for treating germinal center B-cell-like diffuse large B-cell lymphoma, aiming to improve outcomes for patients with this fast-growing blood cancer.
-
Oral Cholesterol-Lowering Peptide Wins Approval After Decade-Long Journey
A new oral peptide therapy designed to help manage cholesterol has received regulatory approval, marking the culmination of ten years of research and development. The milestone offers patients a needle-free option for cardiovascular health support.
-
Ascletis Advances Two Novel Obesity Peptide Candidates with FDA IND Submissions
Ascletis has submitted two Investigational New Drug applications to the FDA for once-monthly injectable peptide therapies targeting obesity, including a novel amylin receptor agonist and a combination formulation with a GLP-1R/GIPR agonist.
-
FDA Advisory Panel Vote Signals Broader Access to Popular Peptides
A recent FDA panel vote suggests millions of Americans could soon see easier access to popular peptide compounds, marking a potential shift in how these therapies are regulated.
-
Nuritas’ PeptiSleep Peptide Shows Promise for Better Sleep and Heart Rate Variability
Nuritas’ PeptiSleep, a bioactive peptide developed using AI-driven discovery methods, has demonstrated improvements in sleep quality and heart rate variability (HRV) in recent findings, offering a promising new avenue for natural sleep support.
-
Silk-Derived Peptide Platform Powers New FDA-Cleared Therapy for Atopic Dermatitis
Evolved By Nature’s peptide-based technology platform has been incorporated into a newly FDA-cleared prescription therapy designed to help manage atopic dermatitis. The milestone highlights growing momentum for peptide science in dermatological care.
-
FDA Advisory Committee Votes to Expand Access to Peptide Therapies
An FDA advisory committee has voted in favor of broadening access to peptide-based treatments, a move that could open the door to wider clinical use in the future.
-
Promising ‘Triple-Agonist’ Weight Loss Peptide Reaching Some Patients Ahead of Full Approval
A next-generation weight-loss therapy that targets three key metabolic hormones is showing strong results in trials, and select patients may gain earlier access through expanded-access pathways ahead of full FDA approval.